AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2517009 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine (1 mg)
Number of subjects: 14
Study 2517009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 814955 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% silver nitrate compresses (SN)
Number of subjects: 0
Study 814955 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% silver sulphadiazine cream (SSD)
Number of subjects: 0
Study 814955 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% silver nitrate and 0.2% chlorhexidine digluconate cream (SNC)
Number of subjects: 0
Study 30702370 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) for 6 weeks with inspiratory loads of 80% of sustained maximal inspiratory pressure (n = 9)
Number of subjects: 14
Study 30702370 — intervention group
Group type: COMPARATOR
Intervention: SHAM protocol for 6 weeks with inspiratory loads of 30% of sustained maximal inspiratory pressure (n = 5)
Number of subjects: 14
Study 27779195 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC interpreted by gastroenterologists
Number of subjects: 1257
Study 27779195 — intervention group
Group type: COMPARATOR
Intervention: CTC interpreted by radiologists
Number of subjects: 1257
Study 27779195 — intervention group
Group type: COMPARATOR
Intervention: CTC interpretation time by radiologists
Number of subjects: 1257
Study 27779195 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC interpretation time by gastroenterologists
Number of subjects: 1257
Study 27779195 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC for pedunculated and sessile lesions
Number of subjects: 1257
Study 27779195 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC for flat elevated lesions ≥10 mm
Number of subjects: 1257
Study 26119844 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D supplementation (1000 mg calcium daily plus 50000 IU vitamin D weekly)
Number of subjects: 104
Study 26119844 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone (1000 mg daily)
Number of subjects: 104
Study 26119844 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D alone (50000 IU weekly)
Number of subjects: 104
Study 26119844 — intervention group
Group type: COMPARATOR
Intervention: Placebo (calcium placebo daily plus vitamin D placebo weekly)
Number of subjects: 104
Study 24354968 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular heroin use prior to imprisonment
Number of subjects: 425
Study 24354968 — intervention group
Group type: COMPARATOR
Intervention: Non-regular heroin use (control group)
Number of subjects: 425
Study 21757915 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomy
Number of subjects: 137
Study 21757915 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 137
Study 19224680 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialogic citizenship education curriculum units
Number of subjects: 482
Study 19224680 — intervention group
Group type: COMPARATOR
Intervention: Regular history classes
Number of subjects: 482
Study 19224680 — intervention group
Group type: EXPERIMENTAL
Intervention: Curriculum unit with more group work
Number of subjects: 482
Study 19224680 — intervention group
Group type: EXPERIMENTAL
Intervention: Curriculum unit with less group work (whole-class teaching)
Number of subjects: 482
Study 16785331 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan (80 to 160 mg)
Number of subjects: 28
Study 16785331 — intervention group
Group type: COMPARATOR
Intervention: atenolol (50 to 100 mg)
Number of subjects: 28
Study 15280154 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg orally four times daily)
Number of subjects: 20
Study 15280154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15280154 — intervention group
Group type: COMPARATOR
Intervention: Lean women
Number of subjects: 20
Study 12004668 — intervention group
Group type: EXPERIMENTAL
Intervention: Condensable composite resin with flowable composite resin as a liner
Number of subjects: 0
Study 12004668 — intervention group
Group type: COMPARATOR
Intervention: Condensable composite resin without flowable composite resin as a liner
Number of subjects: 0
Study 9869984 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed power at 32 watts
Number of subjects: 120
Study 9869984 — intervention group
Group type: COMPARATOR
Intervention: Temperature monitoring with a target temperature of 60 degrees C
Number of subjects: 120
Study 8306661 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (donor-recipient corneal size difference of 0.25 mm)
Number of subjects: 38
Study 8306661 — intervention group
Group type: COMPARATOR
Intervention: Group B (donor-recipient corneal size difference of 0.50 mm)
Number of subjects: 38
Study 8306661 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 38
Study 8306661 — intervention group
Group type: COMPARATOR
Intervention: Group B
Number of subjects: 38
Study 3103761 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow Sodium tablets (100 mmol sodium chloride)
Number of subjects: 15
Study 3103761 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 15
Study 31268376 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg q2w
Number of subjects: 91
Study 31268376 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg q2w
Number of subjects: 91
Study 31268376 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg q2w + csDMARDs
Number of subjects: 91
Study 31268376 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg q2w + csDMARDs
Number of subjects: 91
Study 28756691 — intervention group
Group type: EXPERIMENTAL
Intervention: Word-web intervention (n=11)
Number of subjects: 20
Study 28756691 — intervention group
Group type: COMPARATOR
Intervention: Waiting control (n=9)
Number of subjects: 20
Study 26514790 — intervention group
Group type: EXPERIMENTAL
Intervention: Veterans' In-home Program (VIP) consisting of 6 home visits and 2 telephone calls delivered by occupational therapists over a 3-4 month period.
Number of subjects: 81
Study 26514790 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control group)
Number of subjects: 81
Study 26514790 — intervention group
Group type: EXPERIMENTAL
Intervention: Veterans' In-home Program (VIP)
Number of subjects: 81
Study 26603250 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioural therapy (CBT)
Number of subjects: 297
Study 26603250 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour therapy (BT)
Number of subjects: 297
Study 26603250 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 297
Study 26603250 — intervention group
Group type: COMPARATOR
Intervention: Non‐directive supportive therapy (NDST)
Number of subjects: 297
Study 26603250 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (CBT, BT, MI, NDST)
Number of subjects: 297
Study 22596014 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ω3 and ω6 supplementation
Number of subjects: 0
Study 22596014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21119407 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop group (WG)
Number of subjects: 0
Study 21119407 — intervention group
Group type: COMPARATOR
Intervention: Nonworkshop group (NWG)
Number of subjects: 0
Study 18534136 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination pharmacological cardioversion therapy with low‐dose oral amiodarone (2 mg/kg), captopril (0.25 mg/kg), and simvastatin (0.3 mg/kg) administered daily
Number of subjects: 99
Study 18534136 — intervention group
Group type: COMPARATOR
Intervention: Only ventricular heart rate control
Number of subjects: 99
Study 15777447 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave endometrial ablation (MEA)
Number of subjects: 239
Study 15777447 — intervention group
Group type: COMPARATOR
Intervention: Transcervical resection of the endometrium (TCRE)
Number of subjects: 239
Study 12450897 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mmol glycine/kg lean body mass
Number of subjects: 9
Study 12450897 — intervention group
Group type: COMPARATOR
Intervention: 25 g glucose
Number of subjects: 9
Study 12450897 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mmol glycine/kg lean body mass + 25 g glucose
Number of subjects: 9
Study 12450897 — intervention group
Group type: COMPARATOR
Intervention: Water only
Number of subjects: 9
Study 10512559 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet intervention (group sessions weekly for 6 weeks, biweekly for 6 weeks, and monthly for 9 months)
Number of subjects: 1702
Study 10512559 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet intervention
Number of subjects: 1702
Study 8745134 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion HCL (300 mg/day)
Number of subjects: 149
Study 8745134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 2029827 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol riboside, 25 mg/kg q.i.d. for 13 doses
Number of subjects: 32
Study 2029827 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol riboside
Number of subjects: 32
Study 6988914 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 343
Study 6988914 — intervention group
Group type: EXPERIMENTAL
Intervention: DES
Number of subjects: 343
Study 6988914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study 30793537 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Assessment and Analysis System (PAAS)
Number of subjects: 24
Study 30793537 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PAAS)
Number of subjects: 24
Study 28631923 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoid-rich supplement (329 mg/d)
Number of subjects: 103
Study 28631923 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoid-rich supplement
Number of subjects: 103
Study 28631923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 26098966 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafts procured from donors older than 60 years
Number of subjects: 9724
Study 26098966 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafts from donors with a history of diabetes
Number of subjects: 9724
Study 26098966 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafts from donors with a body mass index of 35 kg/m(2) or more
Number of subjects: 9724
Study 26098966 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafts from donors with severe graft steatosis (more than 60 per cent)
Number of subjects: 9724
Study 26098966 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafts from donation after cardiac death donors with prolonged warm ischaemia
Number of subjects: 9724
Study 24055998 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice a week assessment of home spirometry and CF respiratory symptoms using an electronic device
Number of subjects: 320
Study 24055998 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 320
Study 21335941 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine suppository (60 mg)
Number of subjects: 160
Study 21335941 — intervention group
Group type: COMPARATOR
Intervention: Glycerin suppository (placebo)
Number of subjects: 160
Study 19686930 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-thickness flap reflection
Number of subjects: 40
Study 19686930 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial-thickness flap reflection
Number of subjects: 40
Study 19686930 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoperiosteal flaps (book flap)
Number of subjects: 40
Study 19686930 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-thickness flaps
Number of subjects: 40
Study 19686930 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results of the three flap approaches
Number of subjects: 40
Study 17471064 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham analgesic cream
Number of subjects: 31
Study 17471064 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive cream
Number of subjects: 31
Study 17471064 — intervention group
Group type: COMPARATOR
Intervention: Inactive cream (control)
Number of subjects: 31
Study 15190832 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological organic zinc after routine antibiotic treatment
Number of subjects: 61
Study 15190832 — intervention group
Group type: COMPARATOR
Intervention: Routine antibiotic treatment only
Number of subjects: 61
Study 12370217 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe (10 mg/d)
Number of subjects: 18
Study 12370217 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 9647029 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg twice daily for 7 days
Number of subjects: 120
Study 9647029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 8164924 — intervention group
Group type: EXPERIMENTAL
Intervention: NORPLANT implants
Number of subjects: 10718
Study 2504265 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural fentanyl 50 micrograms
Number of subjects: 27
Study 2504265 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl 50 micrograms
Number of subjects: 27
Study 2504265 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine and adrenaline alone (no fentanyl)
Number of subjects: 27
Study 1252358 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 0
Study 1252358 — intervention group
Group type: COMPARATOR
Intervention: Histamine and papain
Number of subjects: 0
Study 31344296 — intervention group
Group type: EXPERIMENTAL
Intervention: HPC-NL
Number of subjects: 50
Study 31344296 — intervention group
Group type: EXPERIMENTAL
Intervention: HPC-NL + B (10 mg/daily)
Number of subjects: 50
Study 28013124 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect measured after remission
Number of subjects: 107
Study 28013124 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative affect measured after remission
Number of subjects: 107
Study 28013124 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of affect with number of previous depressive episodes
Number of subjects: 107
Study 26167637 — intervention group
Group type: EXPERIMENTAL
Intervention: Early high-volume hemofiltration (HVHF) at 80 ml/kg/h for 48 hours
Number of subjects: 224
Study 26167637 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care with delayed CVVHDF for persistent severe acute kidney injury)
Number of subjects: 224
Study 26167637 — intervention group
Group type: EXPERIMENTAL
Intervention: Early high-volume hemofiltration (HVHF)
Number of subjects: 224
Study 26167637 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 224
Study 26167637 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 224
Study 24011983 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 653
Study 24011983 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence therapy
Number of subjects: 653
Study 24011983 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized cognitive rehabilitation program
Number of subjects: 653
Study 24011983 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 653
Study 24011983 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive abilities
Number of subjects: 653
Study 24011983 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional abilities in activities of daily living
Number of subjects: 653
Study 24011983 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral disturbance
Number of subjects: 653
Study 24011983 — intervention group
Group type: EXPERIMENTAL
Intervention: Apathy
Number of subjects: 653
Study 24011983 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 653
Study 24011983 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 653
Study 24011983 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver's burden
Number of subjects: 653
Study 24011983 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource utilization
Number of subjects: 653
Study 20434290 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Care Model (CCM) intervention
Number of subjects: 119
Study 20434290 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin use
Number of subjects: 119
Study 20434290 — intervention group
Group type: COMPARATOR
Intervention: Medication treatment intensification (TI)
Number of subjects: 119
Study 18249160 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Number of subjects: 0
Study 18249160 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 15872238 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir (2 g twice on the day of treatment and 1 g twice the following day)
Number of subjects: 125
Study 15872238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 12517199 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer group (received nebulized albuterol)
Number of subjects: 168
Study 12517199 — intervention group
Group type: COMPARATOR
Intervention: Spacer group (received albuterol by metered-dose inhaler with a spacer)
Number of subjects: 168
Study 11404902 — intervention group
Group type: EXPERIMENTAL
Intervention: Powder-free glove A
Number of subjects: 10
Study 11404902 — intervention group
Group type: EXPERIMENTAL
Intervention: Powder-free glove B
Number of subjects: 10
Study 11404902 — intervention group
Group type: COMPARATOR
Intervention: Both gloves
Number of subjects: 10
Study 8867518 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine infusion (low, medium, high rates)
Number of subjects: 8
Study 1612153 — intervention group
Group type: COMPARATOR
Intervention: Room air breathing
Number of subjects: 26
Study 1612153 — intervention group
Group type: COMPARATOR
Intervention: Hypoxic mixture
Number of subjects: 26
Study 1612153 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% oxygen
Number of subjects: 26
Study 1612153 — intervention group
Group type: EXPERIMENTAL
Intervention: 21% oxygen
Number of subjects: 26
Study 1612153 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% oxygen
Number of subjects: 26
Study 1612153 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 26
Study 1612153 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxic and hyperoxic conditions
Number of subjects: 26
Study 6200724 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous isosorbide dinitrate infusion (50-200 micrograms/kg/h)
Number of subjects: 18
Study 6200724 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydralazine bolus (0.15 mg/kg)
Number of subjects: 18
Study 6200724 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of isosorbide dinitrate and hydralazine
Number of subjects: 18
Study 6200724 — intervention group
Group type: COMPARATOR
Intervention: Control measurements (1 h)
Number of subjects: 18
Study 29973229 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth decision support system (early-access arm)
Number of subjects: 44
Study 29973229 — intervention group
Group type: COMPARATOR
Intervention: Usual care (later-access arm)
Number of subjects: 44
Study 26474989 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 and oxaliplatin (SOX) therapy
Number of subjects: 663
Study 26474989 — intervention group
Group type: COMPARATOR
Intervention: S-1 and cisplatin (CS) therapy
Number of subjects: 663
Study 24958362 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-inflating resuscitators (FIR)
Number of subjects: 0
Study 24958362 — intervention group
Group type: COMPARATOR
Intervention: Self-inflating resuscitators (SIR)
Number of subjects: 0
Study 22893765 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic and resistance exercise training (n = 27)
Number of subjects: 43
Study 22893765 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity stretching control treatment (n = 16)
Number of subjects: 43
Study 20479483 — intervention group
Group type: EXPERIMENTAL
Intervention: CE+
Number of subjects: 14
Study 20479483 — intervention group
Group type: COMPARATOR
Intervention: PLA
Number of subjects: 14
Study 20479483 — intervention group
Group type: COMPARATOR
Intervention: CE
Number of subjects: 14
Study 19094450 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous supplementation with glutamine dipeptide (Gln) 30 g/day
Number of subjects: 16
Study 19094450 — intervention group
Group type: COMPARATOR
Intervention: Standard amino acid mixture (control) 25 g/day
Number of subjects: 16
Study 16052023 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 14688685 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-hematocrit strategy (21.5% ± 2.9%)
Number of subjects: 147
Study 14688685 — intervention group
Group type: COMPARATOR
Intervention: Higher-hematocrit strategy (27.8% ± 3.2%)
Number of subjects: 147
Study 10939064 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to Mozart for 10 minutes
Number of subjects: 61
Study 10939064 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to Bach for 10 minutes
Number of subjects: 61
Study 10939064 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 61
Study 9079575 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally specific obesity prevention program
Number of subjects: 0
Study 9079575 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo group
Number of subjects: 0
Study 8416561 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonionic low-osmolality contrast medium (iopamidol)
Number of subjects: 70
Study 8416561 — intervention group
Group type: COMPARATOR
Intervention: Ionic high-osmolality contrast medium (sodium diatrizoate)
Number of subjects: 70
Study 3519233 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone
Number of subjects: 40
Study 3519233 — intervention group
Group type: COMPARATOR
Intervention: High-dose metoclopramide
Number of subjects: 40
Study 31613134 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of an adult with SMI
Number of subjects: 6084
Study 31613134 — intervention group
Group type: COMPARATOR
Intervention: Parents of an adult child with DD
Number of subjects: 6084
Study 31613134 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental ambivalence
Number of subjects: 6084